Posted by Michael Wonder on 29 Oct 2022
Almirall announces EMA acceptance for filing of marketing authorisation application for lebrikizumab in atopic dermatitis
28 October 2022 - The EMA application is based on the analysis of Phase 3 studies ADvocate 1&2 and ADhere.
Almirall today announced that the EMA has accepted the filing of the marketing authorisation application for lebrikizumab for the treatment of moderate to severe atopic dermatitis.
